Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

Good point. By December there will be a sufficient number of the appropriate subset of patients (for the first time) dosed with an appropriate amount of 113 (for the first time) to be able to ascertain if 113 is, in fact, effective for the t790m indication (for the first time). Everything that has preceded this phase 2 cohort has been essentially worthless except in terms of establishing tolerability of the drug, but certainly not efficacy. We will have to wait for the results, all else is strictly speculation and conjecture mixed with a pinch of personal bias. My bias is that the December results will be gratifying for the longs.